The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Novikova O.V.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Prokof'eva E.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava RF

Role of chemotherapy in the treatment of aggressive fibromatosis

Authors:

Bolotina L.V., Novikova O.V., Prokof'eva E.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(3): 72‑76

Read: 6176 times

Download PDF (RU)
Contact the author
Table of contents

ROLE OF CHEMOTHERAPY IN THE TREATMENT OF AGGRESSIVE FIBROMATOSIS
ROLE OF CHEMOTHERAPY IN THE TREATMENT OF AGGRESSIVE FIBROMATOSIS

To cite this article:

Bolotina LV, Novikova OV, Prokof'eva EA. Role of chemotherapy in the treatment of aggressive fibromatosis. P.A. Herzen Journal of Oncology. 2012;1(3):72‑76. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Use of HIFU therapy in combination with mono­chemotherapy in a patient with loca­lly adva­nced adenogenic pancreatic cancer and impaired functional status. P.A. Herzen Journal of Onco­logy. 2025;(3):83-88
Evaluation of the skeletal muscle index in predicting toxic complications of anti­tumor drug therapy in patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):29-36
Small cell carcinoma of the paro­tid gland. P.A. Herzen Journal of Onco­logy. 2025;(4):69-74
Resu­lts of testing an antioxidant gel film for the prevention and treatment of palmar-plantar syndrome in cancer patients. P.A. Herzen Journal of Onco­logy. 2025;(5):59-63
Desmoid fibroma in abdo­minal surgery. Piro­gov Russian Journal of Surgery. 2025;(10):126-130
Predictors of arrhythmia and adve­rse outcomes in cancer patients during anti­tumor treatment. Russian Journal of Preventive Medi­cine. 2025;(11):86-93
Prevention and basic therapy of skin toxic reactions in children receiving anti-cancer drug therapy. Part 1. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):828-836
Abstract:

The paper shows the experience of Russian and foreign authors in using various chemotherapy options for aggressive fibromatosis. The regimen of weekly vinblastine-methotrexate administration and the combination of doxorubin and dacarbazine have been most commonly used.

Keywords:

aggressive fibromatosis
desmoid fibroma
chemotherapy

Authors:

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Novikova O.V.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Prokof'eva E.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava RF

Close metadata

References:

  1. Heidemann J., Ogawa H., Otterson M.F., Shidham V.B., Binion D.G. Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. Dis. Colon. Rectum. 2004; 47 (1): 118-22.
  2. Raguse J.D., Gath H.J., Oettle H., Bier J. Interferon-indused remission of rapidly growing aggressive fibromatosis in the temporal fossa. Oral. Maxillofac. Surg. 2004; 33: 606-9.
  3. Tanaka K. et al. Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J. Surg. Oncol. 2008; 6: 17.
  4. Penel N., Le Cesne A., Bui B.N., Perol D., Brain E.G., Ray-Caquard I. et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann. Oncol. 2011; 22 (2): 452-7.
  5. Mace J., Biermann J.S., Sondak V. et al. Response of extraabdominal desmoid tumours to therapy with imatinib mesylate. Cancer. 2002; 95: 2373-9.
  6. Kurtz J.E., Asmane I., Voegeli A.C., Newville A., Dufresne A., Litique V. et al. A V530I mutation in c-KIT exon 10 is associated to imatinib response in extraabdominal aggressive fibromatosis. Sarcoma. 2010: 458156.
  7. Heinrich M., McArthur G.A., Demetri G.D., Joensun H., Bono P., Herrmann R. et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 2006; 24: 1195-203.
  8. Gounder M.M. et al. Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF). J. Clin. Oncol. 2010; 28 (suppl.): 15s; abstr 10013.
  9. Dalén B.P., Geijer M., Kvist H., Bergh P.M., Gunterberg B.U. Clinical and imaging observations of desmoid tumors left without treatment. Acta Orthop. 2006; 77 (6): 932-7.
  10. Weiss J., Lackmann D. Low-dose chemotherapy of desmoid tumors. Cancer. 1989; 64: 1192-4.
  11. Skapek S.X., Hawk B.J., Hoffer F.A., Dahl G.V., Granowetten L., Gebhardt M.C. et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumour in children. J. Clin. Oncol. 1998; 16: 3021-7.
  12. Azzarelli A., Gronchi A., Bertulli R., Tesoro J.D., Baratti D., Pennacehioli E. et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92 (5): 1259-64.
  13. Skapek S.X., Ferguson W.S., Granowetter L., Devidas M., Perez-Atayde A.R., Dehner L.P. et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J. Clin. Oncol. 2007; 25 (5): 501-6.
  14. Al-Otaibi M.L., Turcotte R.E., Hings I., Beandet J., Isler M., Nahal A., Wong C. Low-dose chemotherapy for extra-abdominal desmoid tumor. Saudi Med. J. 2008; 29 (12): 1730-4.
  15. Novikova O.V. Polovye gormony v etiologii, patogeneze i lechenii desmoidnykh fibrom: Avtoref. dis. ... d-ra med. nauk. M.; 2008.
  16. van der Hul R.L., Seynaeve C., van Geel B.N., Verweij J. Low dose methotrexate and vinblastine, given weekly to patients with desmoid tumours. Is associated with major toxicity. Sarcoma. 2003; 7 (3-4): 153-7.
  17. Reich S., Overberg-Schmidt U.S., Bührer C., Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J. Clin. Oncol. 1999; 17 (3): 1086.
  18. Patel S.R., Evans H.L., Benjamin R.S. Combination chemotherapy in adult desmoid tumours. Cancer. 1993; 72: 3244-7.
  19. Schnitzler M., Cohen Z., Blackstein M. et al. Chemotherapy for desmoid tumours in association with familial adenomatous polyposis. Dis. Colon Rectum. 1997; 40: 798-801.
  20. Poritz L.S., Blackstein M., Berk T. et al. Extended follow-up of patients treated with cytotoxic chemotherapy for intraabdominal desmoid tumours. Dis. Colon Rectum. 2001; 44 (9): 1268-73.
  21. Gega M., Yanagi H., Yoshikawa R. et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumours in association with familial adenomatous polyposis. J. Clin. Oncol. 2006; 24 (1): 102-5.
  22. Ezumi K., Yamamoto H., Takemasa I., Nomura M., Ikeda M. et al. Dacarbazine_Doxorubicin therapy Ameliorated an Extremely Aggressive Mesenteric Desmoid Tumor Associated with Familial Adenomatous Pilyposis: report of a case. Jpn. J. Clin. Oncol. 2008; 38 (3): 222-6.
  23. Wehl G., Rossler J., Otten J.E., Boehm N., Whl M. et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Oncologie. 2004; 27: 552-6.
  24. Constantinidou A., Jones R.L., Sewrr M., Al-Muderis O., Judson I. et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur. J. Cancer. 2009; 45 (17): 2928-9.
  25. Goepfert H., Cangir A., Ayala A.G. et al. Chemotherapy of locally aggressive head and neck tumors in the pediatric age group. Am. J. Surg. 1982; 144: 437-44.
  26. Raney B., Evans A., Granowetter L. et al. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics. 1987; 79: 394-8.
  27. Janinis J., Patriki M., Vini L., Aravantinos G., Whelan J.S. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann. Oncol. 2003; 14: 181-90.
  28. Lev-Chelouche D., Abu-Abeid, Nakache R. et al. Limb desmoid tumours: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery. 1999; 126: 963-7.
  29. Gruenhagen D.J., De Wilt J.H., Verhoef C., van Geel A.N., Eggermont A.M. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur. J. Surg. Oncol. 2005; 31 (8): 912-6.
  30. Klaase J.M., Kroon B.B., Benckhuijsen C. et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer. 1989; 64: 616-21.
  31. Gansar G.F., Krementz E.T. Desmoid tumours: experience with new modes of therapy. South. Med. J. 1998; 81: 794-6.
  32. Tsukada K., Church J.M., Jagelman D.G. et al. Systemic cytotoxic chemotherapy and radiation therapy for desmoid tumours in familial adenomatous polyposis. Dis. Colon Rectum. 1991; 34: 1090-2.
  33. Okuno S.H., Edmonson J.H. Combination chemotherapy for desmoid tumours. Cancer. 2003; 97: 1134-35.
  34. Bonvalot S., Mimareix F., Canseret S., Le Péchoux C., Boulet B., Terrier P. et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1_M HILP) is safe and efficient. Ann. Surg. Oncol. 2009; 16 (12): 3350-7.
  35. Reitamo J.J., Hayry P., Nykyri E., Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical disrtribution in the Finnish population. Am. J. Clin. Pathol. 1982; 77: 665-73.
  36. Lynch H.T., Fitzgibbons R., Chong S. et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis. Colon Rectum. 1994; 37: 260-7.
  37. Delépine N., Delépine G., Desbois J.C., Mathé G., Legmann F. Objective response of desmoid fibroma to chemotherapy. Biomed. Pharmacother. 1987; 41: 146-8.
  38. Chissov V.I., Dar'yalova S.L., Boiko A.V., Koroleva L.A. Lechenie desmoidnykh fibrom v Moskovskom nauchno-issledovatel'skom onkologicheskom institute im. P.A. Gertsena (evolyutsiya printsipial'nykh podkhodov v techenie 30 let). Rossiiskii onkologicheskii zhurnal 1997; 3: 13-7.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.